Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response

Publisher： Karger

E-ISSN： 1423-0267|236|2|88-94

ISSN： 0030-3755

Source： Ophthalmologica, Vol.236, Iss.2, 2016-07, pp. : 88-94

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Statins Do Not Decrease the Risk for Wet Age-Related Macular Degeneration

By Kaiserman Nadia Vinker Shlomo Kaiserman Igor

Current Eye Research, Vol. 34, Iss. 4, 2009-04 ,pp. : 304-310

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenetics of the Treatment Response of Age-Related Macular Degeneration with Ranibizumab and Bevacizumab

By Kanoff Justin Miller Joan

Seminars in Ophthalmology, Vol. 28, Iss. 5-6, 2013-09 ,pp. : 355-360

Informa Healthcare

Access to resources Recommend Favorite

Genetic Factors Associated with Age-Related Macular Degeneration

Ophthalmologica, Vol. 226, Iss. 3, 2011-07 ,pp. : 87-102

Karger

Access to resources Recommend Favorite

Mitotropic Compounds for the Treatment of Age-Related Macular Degeneration

Ophthalmologica, Vol. 217, Iss. 5, 2003-08 ,pp. : 351-357

Karger

Access to resources Recommend Favorite

Treatment of Dry Age-Related Macular Degeneration

Ophthalmic Research, Vol. 52, Iss. 3, 2014-09 ,pp. : 107-115

Karger

Access to resources Recommend Favorite